STA
RARE icon

Summit Trail Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Summit Trail Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$739K Buy
22,145
+5,505
+33% +$137K 0.01% 1096
2026
Q1 		$349K Buy
16,640
+2,301
+16% +$51.8K 0.01% 1271
2025
Q4 		$330K Buy
14,339
+5,497
+62% +$181K 0.01% 1190
2025
Q3 		$266K Buy
+8,842
New +$265K ﹤0.01% 1231
2018
Q1 		– Sell
-16
Closed -$1K – 1366
2017
Q4 		$1K Buy
+16
New +$785 ﹤0.01% 1845

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Summit Trail Advisors's RARE Position: Q2 2026 in Review

Summit Trail Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 33% in Q2 2026, buying an estimated $137K and bringing the position to 22,145 shares worth $739K. The position accounts for 0.01% of the portfolio, ranked #1096.

Summit Trail Advisors first reported a position in RARE in Q4 2017 and has held it in 5 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Summit Trail Advisors held 22,145 shares of Ultragenyx Pharmaceutical worth $739K as of Q2 2026.
  • Summit Trail Advisors bought 5,505 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $137K.
  • Ultragenyx Pharmaceutical made up 0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1096 holding.
  • Summit Trail Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and has held it in 5 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.